Copyright Reports & Markets. All rights reserved.

Global Rheumatic Disorders Drug Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Rheumatic Disorders Drug Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Acting on Tumor Necrosis Factor-Alpha
      • 1.4.3 Acting on Interleukins and Interleukin Receptors
      • 1.4.4 Acting on Protein Kinases
      • 1.4.5 Acting on Cell Surface Antigens
      • 1.4.6 Acting on Hormones and Hormone Receptors
      • 1.4.7 Others
    • 1.5 Market by Application
      • 1.5.1 Global Rheumatic Disorders Drug Market Share by Application (2019-2025)
      • 1.5.2 Rheumatoid Arthritis
      • 1.5.3 Osteoarthritis
      • 1.5.4 Osteoporosis
      • 1.5.5 Systemic Lupus Erythematosus
      • 1.5.6 Psoriatic Arthritis
      • 1.5.7 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Rheumatic Disorders Drug Market Size
    • 2.2 Rheumatic Disorders Drug Growth Trends by Regions
      • 2.2.1 Rheumatic Disorders Drug Market Size by Regions (2019-2025)
      • 2.2.2 Rheumatic Disorders Drug Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Rheumatic Disorders Drug Market Size by by Players
      • 3.1.1 Global Rheumatic Disorders Drug Revenue by by Players (2014-2019)
      • 3.1.2 Global Rheumatic Disorders Drug Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Rheumatic Disorders Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Rheumatic Disorders Drug Key Players Head office and Area Served
    • 3.3 Key Players Rheumatic Disorders Drug Product/Solution/Service
    • 3.4 Date of Enter into Rheumatic Disorders Drug Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Rheumatic Disorders Drug Market Size by Type (2014-2019)
    • 4.2 Global Rheumatic Disorders Drug Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Rheumatic Disorders Drug Market Size (2014-2019)
    • 5.2 Rheumatic Disorders Drug Key Players in North America
    • 5.3 North America Rheumatic Disorders Drug Market Size by Type
    • 5.4 North America Rheumatic Disorders Drug Market Size by Application

    6 Europe

    • 6.1 Europe Rheumatic Disorders Drug Market Size (2014-2019)
    • 6.2 Rheumatic Disorders Drug Key Players in Europe
    • 6.3 Europe Rheumatic Disorders Drug Market Size by Type
    • 6.4 Europe Rheumatic Disorders Drug Market Size by Application

    7 China

    • 7.1 China Rheumatic Disorders Drug Market Size (2014-2019)
    • 7.2 Rheumatic Disorders Drug Key Players in China
    • 7.3 China Rheumatic Disorders Drug Market Size by Type
    • 7.4 China Rheumatic Disorders Drug Market Size by Application

    8 Japan

    • 8.1 Japan Rheumatic Disorders Drug Market Size (2014-2019)
    • 8.2 Rheumatic Disorders Drug Key Players in Japan
    • 8.3 Japan Rheumatic Disorders Drug Market Size by Type
    • 8.4 Japan Rheumatic Disorders Drug Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Rheumatic Disorders Drug Market Size (2014-2019)
    • 9.2 Rheumatic Disorders Drug Key Players in Southeast Asia
    • 9.3 Southeast Asia Rheumatic Disorders Drug Market Size by Type
    • 9.4 Southeast Asia Rheumatic Disorders Drug Market Size by Application

    10 India

    • 10.1 India Rheumatic Disorders Drug Market Size (2014-2019)
    • 10.2 Rheumatic Disorders Drug Key Players in India
    • 10.3 India Rheumatic Disorders Drug Market Size by Type
    • 10.4 India Rheumatic Disorders Drug Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Rheumatic Disorders Drug Market Size (2014-2019)
    • 11.2 Rheumatic Disorders Drug Key Players in Central & South America
    • 11.3 Central & South America Rheumatic Disorders Drug Market Size by Type
    • 11.4 Central & South America Rheumatic Disorders Drug Market Size by Application

    12 International Players Profiles

    • 12.1 AbbVie
      • 12.1.1 AbbVie Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Rheumatic Disorders Drug Introduction
      • 12.1.4 AbbVie Revenue in Rheumatic Disorders Drug Business (2014-2019))
      • 12.1.5 AbbVie Recent Development
    • 12.2 Amgen
      • 12.2.1 Amgen Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Rheumatic Disorders Drug Introduction
      • 12.2.4 Amgen Revenue in Rheumatic Disorders Drug Business (2014-2019)
      • 12.2.5 Amgen Recent Development
    • 12.3 Johnson & Johnson
      • 12.3.1 Johnson & Johnson Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Rheumatic Disorders Drug Introduction
      • 12.3.4 Johnson & Johnson Revenue in Rheumatic Disorders Drug Business (2014-2019)
      • 12.3.5 Johnson & Johnson Recent Development
    • 12.4 Novartis
      • 12.4.1 Novartis Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Rheumatic Disorders Drug Introduction
      • 12.4.4 Novartis Revenue in Rheumatic Disorders Drug Business (2014-2019)
      • 12.4.5 Novartis Recent Development
    • 12.5 Pfizer
      • 12.5.1 Pfizer Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Rheumatic Disorders Drug Introduction
      • 12.5.4 Pfizer Revenue in Rheumatic Disorders Drug Business (2014-2019)
      • 12.5.5 Pfizer Recent Development
    • 12.6 Roche
      • 12.6.1 Roche Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Rheumatic Disorders Drug Introduction
      • 12.6.4 Roche Revenue in Rheumatic Disorders Drug Business (2014-2019)
      • 12.6.5 Roche Recent Development
    • 12.7 Eli Lilly
      • 12.7.1 Eli Lilly Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Rheumatic Disorders Drug Introduction
      • 12.7.4 Eli Lilly Revenue in Rheumatic Disorders Drug Business (2014-2019)
      • 12.7.5 Eli Lilly Recent Development
    • 12.8 Bristol-Myers Squibb
      • 12.8.1 Bristol-Myers Squibb Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Rheumatic Disorders Drug Introduction
      • 12.8.4 Bristol-Myers Squibb Revenue in Rheumatic Disorders Drug Business (2014-2019)
      • 12.8.5 Bristol-Myers Squibb Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Treatment of drugs for regulating rheumatic diseases
      Rheumatic diseases are a series of diseases characterized by chronic pain. Some of the most common diseases are osteoarthritis (OA) and rheumatoid arthritis (RA), and most rheumatic diseases use basically universal pain control drugs. Treatment is ongoing and there are no treatments for any of the key indications, so there is a need to develop better disease modulating drugs.
      In 2018, the global Rheumatic Disorders Drug market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Rheumatic Disorders Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Rheumatic Disorders Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      AbbVie
      Amgen
      Johnson & Johnson
      Novartis
      Pfizer
      Roche
      Eli Lilly
      Bristol-Myers Squibb

      Market segment by Type, the product can be split into
      Acting on Tumor Necrosis Factor-Alpha
      Acting on Interleukins and Interleukin Receptors
      Acting on Protein Kinases
      Acting on Cell Surface Antigens
      Acting on Hormones and Hormone Receptors
      Others

      Market segment by Application, split into
      Rheumatoid Arthritis
      Osteoarthritis
      Osteoporosis
      Systemic Lupus Erythematosus
      Psoriatic Arthritis
      Others

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Rheumatic Disorders Drug status, future forecast, growth opportunity, key market and key players.
      To present the Rheumatic Disorders Drug development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Rheumatic Disorders Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now